Hisense Bio

About Hisense Bio

HysensBio is a South Korean biotechnology company founded in 2016 that develops therapeutic products for dental diseases. The company is focused on creating first-in-class treatments for conditions like dentin hypersensitivity, dental caries, and periodontal disease. Their core technology is based on over two decades of dental research and revolves around the regeneration of physiologic dentin and the periodontal ligament.

The company's primary technology platform, Dentopine, utilizes a peptide, KH-001, to reactivate odontoblasts (dentin-forming cells). This process is designed to block exposed dentinal tubules and generate new dentin, thereby treating the root cause of tooth sensitivity and pain. This regenerative approach aims to provide a fundamental solution for dental caries and hypersensitivity. HysensBio is developing this technology into various applications, including specialized liniments, home oral care products like toothpaste and mouthwash, and as an additive to dental restorative materials. Another platform, PACA (Permanent Adult Cell Activation), aims to apply similar cell reactivation principles to other incurable diseases beyond the dental field.

HysensBio was established based on research on dentin regeneration that began in 1999, leading to the identification of a native dentin regenerative protein and the subsequent development of a functional peptide in 2016. The company has secured patents for its technology and has received funding from institutional investors, including Daily Partners and Korea Investment Holdings. HysensBio collaborates with research institutions like Seoul National University and has established R&D partnerships in the United States, China, and Japan to advance its product development and business operations.